Aminoheterocyclic derivatives as antithrombotic or anticoagulant
    31.
    发明授权
    Aminoheterocyclic derivatives as antithrombotic or anticoagulant 失效
    氨基杂环衍生物作为抗血栓形成或抗凝血剂

    公开(公告)号:US5965559A

    公开(公告)日:1999-10-12

    申请号:US817031

    申请日:1997-03-26

    摘要: The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

    摘要翻译: PCT No.PCT / GB95 / 02285第 371日期1997年3月26日 102(e)1997年3月26日PCT PCT 1995年9月25日PCT公布。 WO96 / 10022 PCT出版物 日期:1996年4月4日本发明涉及式(I)化合物,其中,G1,G2和G6各自为CH或n; m为1或2; R1包括氢,卤代和(1-4C)烷基; M1为式(Ⅱ)所示的基团,其中R2和R3一起形成(1-4C)亚烷基,L1包括(1-4C)亚烷基,且T1为CH或N; A可能是直接链接; M2是下式的基团:(T2R4)r-L2T3R5其中R是0或1,每个T2和T3是CH或N,每个R4和R5分别是氢或(1-4C)烷基,或R4和 R5一起形成(1-4C)亚烷基,L2包括(1-4C)亚烷基; M3可能直接连接到X; X包括磺酰基; Q包括萘基和杂环部分; 或其药学上可接受的盐; 其制备方法,含有它们的药物组合物及其作为抗血栓形成或抗凝血剂的用途。

    6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof
    37.
    发明授权
    6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof 失效
    6-取代的4-羟基噌啉-3-基羧酸及其酯

    公开(公告)号:US4045439A

    公开(公告)日:1977-08-30

    申请号:US626531

    申请日:1975-10-28

    CPC分类号: C07D237/28

    摘要: 6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof, processes for their preparation, and pharmaceutical compositions comprising any one of these compounds. A representative compound is ethyl 6-glycylamino-4-hydroxycinnolin-3-yl carboxylate hydrochloride. The compounds are active as inhibitors of effects following the combination of reagin-like antibodies and their antigens.

    摘要翻译: 6-取代的4-羟基噌啉-3-基羧酸及其酯,其制备方法和包含这些化合物中的任何一种的药物组合物。 代表性的化合物是6-甘氨酰氨基-4-羟基噌啉-3-基羧酸乙酯盐酸盐。 这些化合物作为抑制剂作为效应的抑制剂,与抗原样抗体及其抗原组合。